DellaCamera reports 7.8% stake in Enzon Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., Nov. 19 - Enzon Pharmaceuticals, Inc. investors led by DellaCamera Capital Master Fund, Ltd. increased their beneficial ownership of the company to 7.8%, or 3,553,558 shares, it was reported in a schedule 13D/A filed with the Securities and Exchange Commission.

DellaCamera bought 174,735 shares between Oct. 17 and Nov. 12 at prices from $3.01 to $5.08 each.

In a prior SEC filing, DellaCamera said it was encouraged by the company's exploration of strategic alternatives for its specialty pharmaceuticals division, a step the investor had previously advocated.

Enzon is a Bridgewater, N.J.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.